Sorafenib mitigates tauopathy via multiple pathways: sorafenib inhibits various kinases to reduce tau phosphorylation, enhances autophagy-mediated tau degradation, and upregulates FBXW7 to promote the ubiquitin-proteasome degradation of ptau231. This evidence concerns the gene MAPT and tauopathy.